References
- Forsea AM. Melanoma Epidemiology and early detection in Europe: diversity and disparities," (in eng. Dermatol Pract Concept. 2020;10(3):e2020033.
- Wanner M, Matthes KL, Karavasiloglou N, et al. 37-year incidence and mortality time trends of common cancer types by sex, age, and stage in the canton of Zurich. Swiss Med Wkly. 2020;150:w20388.
- Schweiz K. Krebs in der Schweiz: wichtige Zahlen. 2022. https://www.krebsliga.ch/ueber-krebs/zahlen-fakten/-dl-/fileadmin/downloads/sheets/zahlen-krebs-in-der-schweiz.pdf
- Skin Cancer Foundation. Melanoma stages, diagnosis and staging. what it means for you. 2022. https://www.skincancer.org/skin-cancer-information/melanoma/the-stages-of-melanoma/
- Melanoma Research Alliance. Stage 2 melanoma. 2022. https://www.curemelanoma.org/about-melanoma/melanoma-staging/stage-2
- Miller R, Walker S, Shui I, et al. Epidemiology and survival outcomes in stages II and III cutaneous melanoma: a systematic review. Melanoma Manag. 2020;7(1):Mmt39.
- Bleicher J, Swords DS, Mali ME, et al. Recurrence patterns in patients with stage II melanoma: the evolving role of routine imaging for surveillance," (in eng. J Surg Oncol. 2020;122(8):1770–1777.
- Christoffersen P, Khan N, Lucas J, et al. Estimation of direct medical costs associated with treatment of metastatic melanoma in Switzerland. Value in Health. 2015;18(7):A451.
- Gershenwald JE, Scolyer RA. Melanoma staging: American joint committee on cancer (AJCC) 8th edition and beyond," (in eng. Ann Surg Oncol. 2018;25(8):2105–2110.
- Michielin O, van Akkooi ACJ, Ascierto PA, ESMO Guidelines Committee. Electronic address: [email protected], et al. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(12):1884–1901.
- Trinh VA, Zobniw C, Hwu WJ. The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma. Expert Opin Drug Saf. 2017;16(8):933–940.
- Ives NJ, Suciu S, Eggermont AMM, International Melanoma Meta-Analysis Collaborative Group (IMMCG), et al. Adjuvant interferon-alpha; for the treatment of high-risk melanoma: an individual patient data meta-analysis. Eur J Cancer. 2017;82:171–183.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology - Melanoma: Cutaneous. Version 1. 2022. NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
- Krensel M, Schäfer I, Augustin M. Cost-of-illness of melanoma in Europe – a systematic review of the published literature. J Eur Acad Dermatol Venereol. 2019;33(3):504–510.
- Sanmamed MF, Chen L. A Paradigm shift in cancer immunotherapy: from enhancement to normalization," (in eng). Cell. 2018;175(2):313–326.
- Eggermont AMM, Kicinski M, Blank CU, et al. Pembrolizumab versus placebo after complete resection of High-Risk stage III melanoma: 5-Year results of the EORTC 1325-MG/KEYNOTE-054 Double-Blinded phase 3 trial," in ESMO congress 2022, paris, France. Ann Oncol. 2022;33(Suppl_7):S912–S913.
- Luke JJ, Ascierto PA, Carlino MS, et al. KEYNOTE-716: phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma," (in eng). Future Oncol. 2020;16(3):4429–4438.
- ClinicalTrials.gov. Safety and efficacy of pembrolizumab compared to placebo in resected high-risk stage II melanoma (MK-3475-716/KEYNOTE-716). 2022. https://clinicaltrials.gov/ct2/show/NCT03553836
- Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. The Lancet. 2022;399(10336):1718–1729.
- Food and Drug Administration. FDA approves pembrolizumab for adjuvant treatment of Stage IIB or IIC melanoma. 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-adjuvant-treatment-stage-iib-or-iic-melanoma#:∼:text=FDA%20approves%20pembrolizumab%20for%20adjuvant%20treatment%20of%20Stage%20IIB%20or%20IIC%20melanoma,-Share&text=On%20December%203%2C%202021%2C%20the,IIC%20melanoma%20following%20complete%20resection
- European Medicines Agency. Product information. 2022. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf
- RefData. Keytruda® product information (Switzerland). 2022. https://www.swissmedicinfo.ch/#section1
- Bundesamt für Gesundheit (BAG). BAG-bulletin. 2019. https://www.bag.admin.ch/bag/de/home/das-bag/publikationen/periodika/bag-bulletin.html
- ScienceIndustries Switzerland. Verhaltenskodex der pharmazeutischen Industrie in der Schweiz (Pharmakodex): Regel 26. 2022. https://www.scienceindustries.ch/_file/27931/Pharmakodex_Version_Mai%202020_D.pdf
- Bhadhuri A, Insinga R, Guggisberg P, et al. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland," (in eng. Swiss Med Wkly. 2019;149:w20170.
- Barbier M, Durno N, Bennison C, et al. Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland. Eur J Health Econ. 2022;23(5):837–846.
- Schur N, Gudala K, Vudumula U, et al. Cost effectiveness and budget impact of siponimod compared to interferon beta-1a in the treatment of adult patients with secondary progressive multiple sclerosis with active disease in Switzerland. PharmacoEconomics. 2021;39(5):563–577.
- Bommer C, Lupatsch J, Bürki N, et al. Cost–utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland. Eur J Health Econ. 2022;23(5):807–821.
- Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the european organisation for research and treatment of cancer 18071 double-blind phase 3 randomised trial," (in eng). Eur J Cancer. Sep 2019;119:1–10.
- Suciu S, Eggermont AMM, Lorigan P, et al. Relapse-free survival as a surrogate for overall survival in the evaluation of stage II-III melanoma adjuvant therapy. J Natl Cancer Inst. 2018;110:87–96.
- Coart E, Suciu S, Squifflet P, et al. Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors. Eur J Cancer. 2020;137:171–174.
- Hinchliffe SR, Lambert PC. Flexible parametric modelling of cause-specific hazards to estimate cumulative incidence functions. BMC Med Res Methodol. 2013;13(1):13–14.
- National Institute for Health and Care Excellence. DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review. 2022. https://www.sheffield.ac.uk/nice-dsu
- Bajaj S, Donnelly D, Call M, et al., Melanoma Prognosis: accuracy of the American joint committee on cancer staging manual eighth edition, J Natl Cancer Inst, 2020;112(9):921–928.
- Samlowski W, Silver MA, Hohlbauch A, et al. Real-world clinical outcomes of patients with stage IIB and IIC cutaneous melanoma treated at US community oncology clinics. Future Oncol. 2022;18(33):3755–3767.
- Chaudhuri M. Utility Analysis report for KN716-CSR3 Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: report adapted for Germany. 2022.
- Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13(5):509–518.
- Ludwig K, Graf von der Schulenburg J, Greiner W. German value set for the EQ-5D-5L. Pharmacoeconomics. 2018;36(6):663–674.
- F. S. Office. Consumer prices. 2022. https://www.bfs.admin.ch/bfs/de/home/statistiken/preise/landesindex-konsumentenpreise.assetdetail.21784714.html
- Larkin A, Algurafi A, Barlow B. Position paper: follow-up of high risk cutaneous melanoma in the UK. 2022. https://melanomafocus.org/melanoma-patient-treatment-guide/
- National Institute for Health and Care Excellence. Melanoma: assessment and management: NICE guideline [NG14]. 2022. https://www.nice.org.uk/guidance/ng14
- Kanaki T, Stang A, Gutzmer R, et al. Impact of American joint committee on cancer 8th edition classification on staging and survival of patients with melanoma. Eur J Cancer. 2019;119:18–29.
- Aguiar-Ibáñez R, Wang J, Bensimon A, et al. Challenges and good practices when modeling CostEffectiveness of novel (neo-) adjuvant oncology therapies in health technology appraisals (HTAs). ISPOR Workshop. 2020.
- Crott R, Ali F, Burdette-Radoux S. Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec. Value Health. 2004;7(4):423–432.
- Cormier JN, Xing Y, Ding M, et al. Cost Effectiveness of adjuvant interferon in Node-Positive melanoma. J Clin Oncol. 2007;25(17):2442–2448.
- Dixon S, Walters SJ, Turner L, et al. Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial. Br J Cancer. 2006;94(4):492–498.
- González-Larriba JL, Serrano S, Alvarez-Mon M, et al. Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain. Eur J Cancer. 2000;36(18):2344–2352.
- Hillner BE, Kirkwood JM, Atkins MB, et al. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern cooperative oncology group 1684. J Clin Oncol. 1997;15(6):2351–2358.
- Clarke CS, Hunter RM, Shemilt I, et al. Multi-arm Cost-Effectiveness analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective. PLoS One. 2017;12(3):e0172731.
- Erman A, Nugent A, Amir E, et al. Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer. Breast Cancer Res Treat. 2014;145(2):267–279.
- Hedden L, O'Reilly S, Lohrisch C, et al. Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer," (in eng. Oncologist. 2012;17(2):164–171.
- Salikhanov I, Heinimann K, Chappuis P, et al. Swiss cost-effectiveness analysis of universal screening for lynch syndrome of patients with colorectal cancer followed by Cascade genetic testing of relatives. J Med Genet. 2022;59(9):924–930.
- U.S. Department of Veterans Affairs. Measuring costs for cost-effectiveness analysis. 2022. https://www.herc.research.va.gov/include/page.asp?id=measure-costs-cea
- Khattak MA, Luke JJ, Long GV, et al. Health-related quality of life (HRQoL) with pembrolizumab (pembro) in resected high-risk stage II melanoma in the phase 3 KEYNOTE-716 study. American Society of Clinical Oncology. 2022.
- Bottomley A, Coens C, Mierzynska J, EORTC Melanoma Group, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(5):655–664.
- Bertram MY, Lauer JA, Stenberg K, et al. Methods for the economic evaluation of health care interventions for priority setting in the health system: an update from WHO CHOICE. Int J Health Policy Manag. 2021;10(11):673–677.
- National Institute for Health and Care Excellence. DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. 2022. https://www.sheffield.ac.uk/nice-dsu
- Schwenkglenks M, Matter-Walstra K. Is the EQ-5D suitable for use in oncology? An overview of the literature and recent developments. Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):207–219.
- Bhadhuri A, Kind P, Salari P, et al. Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy," (in eng. Health Qual Life Outcomes. 2020;18(1):317.
- Koruth R, Sharma R, Kanters S, et al. Establishing the relationship between relapse-free survival and overall survival in adjuvant high-risk radically resected cutaneous melanoma. In: The Society for Melanoma Research, Fifteenth International Congress, Manchester, England, 2018.
- Long GV, Luke JJ, Khattak MA, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial," (in eng. Lancet Oncol. 2022;23(11):1378–1388.
- National Institute for Health and Care Excellence. Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma: Technology appraisal guidance [TA837]. 2022. https://www.nice.org.uk/guidance/TA837
- Hematology/Oncology. Adjuvant pembrolizumab shows benefit in patients with resected stage IIB, IIC melanoma. 2022. https://www.healio.com/news/hematology-oncology/20220606/adjuvant-pembrolizumab-shows-benefit-in-patients-with-resected-stage-iib-iic-melanoma
- Goodman A. Adjuvant pembrolizumab for high-risk stage II melanoma: Efficacy and safety examined. 2022. https://ascopost.com/news/september-2021/adjuvant-pembrolizumab-for-high-risk-stage-ii-melanoma-efficacy-and-safety-examined/#:∼:text=The%20current%20standard%20of%20care,stage%20IIIA%20and%20IIIB%20melanoma